Podcast Episodes
Back to Search
Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals
Interim CEO Magda Jonikas describes Mosaic's platform and the rationale behind these two targets the company has licensed in.
1 year, 4 months ago
Cambridge, UK based Epitopia is helping Merck (MSD) discover tumor associated antigens from the non-coding regions of the genome using its CryptoMap platform
CEO Alan Rigby talks about the work Epitopia does finding "Crypotgen" antigens for its own off-the-shelf cancer vaccines, and discusses what was appe…
1 year, 4 months ago
Munich based Tubulis is working on ADCs that it believes are more durable, potent, and homogenous than others on the market currently - it has signed partnerships with Gilead and Bristol
Co-Founder and CEO Dominik Schumacher describes what he thinks can be improved on from the current generation of antibody-drug conjugates, and the sc…
1 year, 4 months ago
As the field builds on the initial success of PARP inhibitors, Artios Pharma is working on the next generation of DNA Damage Response (DDR)-based therapies - it just had clinical data on one at AACR
CEO Niall Martin walks us through the current state of this corner of drug development, and then highlights data presented at AACR last week for its …
1 year, 4 months ago
Munich based ITM Radiopharma is progressing towards a first NDA in the U.S. with a robust pipeline behind it - all the while making investments in isotope manufacturing that has slowed others
CEO Andrew Cavey describes how ITM has been investing to avoid the shortages others have experienced, and explains how the supply chain works for rad…
1 year, 4 months ago
Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization
CEO Carsten Rudolph and CMO Thomas Langenickel describe the technology, which can be spray dried and shipped in a dry powder formulation, and also th…
1 year, 4 months ago
Swiss Biotech Day: Geneva based Light Chain Bioscience is developing bi-specifics that integrate two light chains into its structure with the goal of having a more native format
CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly have a CD47…
1 year, 4 months ago
Swiss Biotech Day: Milan based Genenta Science recently raised €20 million from a government investment fund as it takes its cell therapy into the clinic in renal cell carcinoma
Co-Founder and CEO Pierluigi Paracchi describes the terms of the convertible bond raise, which gives the investor, ENEA Tech and Biomedical, the oppo…
1 year, 4 months ago
Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering
Chairman & CEO Emmanuel Savioz describes the benefits of decentralized manufacturing that is at or near the site of treatment. He highlights an armor…
1 year, 4 months ago
Swiss Biotech Day: Lausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria
CEO Klaus Dugi describes why the company is focused on mitochondria and how it using small molecules to fix them. He covers the three main disease ar…
1 year, 4 months ago